Deep Lens Inc.

Deep Lens Inc. specializes in utilizing artificial intelligence to enhance the clinical trial process, connecting patients, healthcare providers, and sponsors to streamline research workflows. Deep Lens Inc. was founded in 2017 and is headquartered in Columbus, US.

The company offers an innovative platform that focuses on improving clinical trials by enhancing patient care and connectivity. The founders include Dave Billiter, Simon Arkell, and TJ Bowen. In January 2023, Deep Lens Inc. was acquired by Paradigm Health, Inc.

from investors including Rev1 Ventures and Northpond Ventures, securing a total of USD 14. 00 mn in funding through the Series A round led by Northpond Ventures. Deep Lens Inc. provides a research platform designed to optimize the clinical trial process by improving patient care.

Its suite of tools facilitates effective connections among patients, healthcare providers, and sponsors, addressing challenges like patient enrollment and trial management. The platform caters to a diverse clientele, including pharmaceutical companies and clinical research institutions mainly in North America and Europe, helping them deliver innovative therapies and improve patient access to clinical research. Deep Lens Inc. generates revenue through a B2B model, primarily offering subscription-based access to its research platform.

Clients pay fees to utilize various services tailored to their clinical trial needs. The company may also engage in collaborations with pharmaceutical sponsors that involve shared revenue opportunities tied to successful trial outcomes, thereby enhancing trial efficiency and patient engagement. Following the acquisition by Paradigm Health, Inc. in January 2023, Deep Lens Inc.

aims to leverage recent funding to expand its offerings and reach. The company plans to develop new features for its platform and enhance its service capabilities to cater to an increasing client base. Additionally, Deep Lens Inc. is targeting expansion into new markets, particularly in Europe, by the end of 2024, to further support clinical research initiatives globally.